TOP > News Release
News Release

News Release

Browse by Year
2008
2007
2006
2005
Browse by Category
Corporate
R&D
Products
Others
Guide to Category Symbols
Corporate
R&D
Products
Others
2008.04.16
Welchol(R) Added to the American College of Endocrinology/American Association of Clinical Endocrinologists "Road Maps to Achieve Glycemic Control in Patients with Type 2 Diabetes Mellitus"
2008.03.31
Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
2008.03.26
Joint Research of Antibody Drugs with MorphoSys to be Expanded
2008.03.12
Luitpold Pharmaceutical's INJECTAFER(TM)
(ferric carboxymaltose injection) receives non-approvable letter from FDA
2008.03.12
The Percutaneous Absorption-Type Analgesic and Anti-inflammatory Drug Loxonin(R)Tape 50mg/100mg
Receives Approval for Manufacture and Marketing
2008.03.05
Japanese pharmaceutical company acquires osteoporosis medication EVISTA from Lilly
DAIICHI SANKYO presses ahead with European expansion
2008.03.03
DAIICHI SANKYO Notice on Organizational Restructuring as of April 1, 2008
2008.02.22
FDA grants priority review for Daiichi Sankyo, Lilly drug, prasugrel
Investigational antiplatelet agent submitted for treatment of patients with acute coronary syndrome being managed with percutaneous coronary intervention
2008.02.20
Daiichi Sankyo, Lilly Submit Marketing Authorization Application for
Investigational Oral Antiplatelet Drug, Prasugrel, to European
Medicines Agency
2008.02.15
DAIICHI SANKYO Notice concerning Determination of Certain Terms of the Issue Stock Options
(Stock Acquisition Rights) as Remuneration
2008.02.04
FDA Advisory Committee Supports Favorable Risk-Benefit Profile for Injectafer(TM)(Ferric Carboxymaltose Injection) Under Certain Indications for Use
2008.02.01
Analytical Results for Women from Large Scale Clinical Trial MEGA Study Employing the Hypercholesterolemia Drug Mevalotin(R) Published
2008.01.31
DAIICHI SANKYO to Issue Stock Options (Stock Acquisition Rights) as
Remuneration
2008.01.28
Broad-spectrum Oral Antibacterial Agent
Gracevit(R) tablets 50mg/fine granules 10%
Receives Approval for Manufacturing and Marketing
2008.01.21
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
2008.01.07
Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet
Drug, Prasugrel, with U.S. Food and Drug Administration
If Approved for Marketing in the United States, Trade Name Will be Effient(TM)
2007.12.21
DAIICHI SANKYO to Dissolve Subsidiary
2007.12.21
DAIICHI SANKYO Announces Merger of Subsidiaries
2007.11.30
Share Transfer of NIPPON NYUKAZAI and SINO-JAPAN CHEMICAL
(subsidiaries of DAIICHI SANKYO)
2007.11.04
In Landmark Phase III Head-to-Head Study, Prasugrel Statistically
Superior to Clopidogrel in Reducing Risk of Heart Attack
2007.11.04
Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel
2007.10.26
DAIICHI SANKYO Announces the Revisions of Financial Forecasts for FY2007
2007.10.25
Study Protocols Will be Amended in Two Small Early-Phase Prasugrel Studies
2007.10.01
DAIICHI SANKYO EUROPE is applying for approval of its new
combination product of Olmesartan and Amlodipin
2007.09.28
Application Filed for Additional Indication for Selective Antithrombin Agents Novastan(R) HI Injection 10mg/2mL and Slonnon(R) HI Injection 10mg/2mL for Heparin-Induced Thrombocytopenia
2007.09.28
AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure
2007.08.29
Deal for Irinotecan Hydrochloride with Yakult Honsha Terminates
2007.08.28
Additional Pediatric Indication for Fentanyl Injection Approved
Japan's First Ever Approval of Physician-led Clinical Trial
2007.08.22
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
2007.07.31
DAIICHI SANKYO Announces Results of Share Buyback
Browse by Year
2008
2007
2006
2005
Browse by Category
Corporate
R&D
Products
Others